Select therapeutic use:

Asthma/COPD:

Indications for DUPIXENT:

As an add-on maintenance treatment in patients with moderate to severe asthma with an eosinophilic phenotype or with oral corticosteroid dependent asthma.

Limitations of Use:

Not for relief of acute bronchospasm or status asthmaticus.

Adult:

Give by SC inj into thigh, abdomen (except around navel), or upper arm; rotate inj sites. Initially 400mg (two 200mg inj at different sites) followed by 200mg every other week; or, initially 600mg (two 300mg inj at different sites) followed by 300mg every other week. For those with oral corticosteroids-dependent asthma or with co-morbid moderate to severe atopic dermatitis for which Dupixent is indicated: initially 600mg followed by 300mg every other week.

Children:

<12yrs: not established.

Warnings/Precautions:

Discontinue if significant hypersensitivity reaction occurs; treat appropriately. Advise patients to report new onset or worsening eye symptoms. Avoid abrupt discontinuation of any corticosteroids upon Dupixent initiation. Atopic dermatitis or CRSwNP patients with co-morbid asthma. Treat pre-existing helminth infections prior to initiation; if infection develops and unresponsive to anthelmintics, discontinue Dupixent until resolves. Do not inject into tender, damaged, bruised or scarred skin. Pregnancy. Nursing mothers.

Pharmacologic Class:

Interleukin-4 receptor alpha antagonist.

Interactions:

Avoid concomitant live vaccines.

Adverse Reactions:

Inj site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, oropharyngeal pain, eosinophilia, insomnia, toothache, gastritis, arthralgia; hypersensitivity.

Generic Availability:

NO

How Supplied:

Single-dose prefilled syringes—2 (with needle shield)

Pricing for DUPIXENT

2 syringes of 150mg/ml carton (Qty: 2)
Appx. price $2980
GoodRx

Miscellaneous dermatological conditions:

Indications for DUPIXENT:

Moderate to severe atopic dermatitis in patients who are not adequately controlled with topical prescription therapies or when they are not advisable.

Adults and Children:

<6yrs: not established. Give by SC inj into thigh, abdomen (except around navel), or upper arm; rotate inj sites. 6–17yrs (15–<30kg): initially 600mg (two 300mg inj at different sites) followed by 300mg every 4 weeks; (30–<60kg): initially 400mg (two 200mg inj at different sites) followed by 200mg every other week; (≥60kg): initially 600mg (two 300mg inj at different sites) followed by 300mg every other week. ≥18yrs: initially 600mg (two 300mg inj at different sites) followed by 300mg every other week. May use with or without topical corticosteroids. Topical calcineurin inhibitors may also be used, but should be reserved only for problem areas (eg, face, neck, intertriginous and genital areas).

Warnings/Precautions:

Discontinue if significant hypersensitivity reaction occurs; treat appropriately. Advise patients to report new onset or worsening eye symptoms. Avoid abrupt discontinuation of any corticosteroids upon Dupixent initiation. Atopic dermatitis or CRSwNP patients with co-morbid asthma. Treat pre-existing helminth infections prior to initiation; if infection develops and unresponsive to anthelmintics, discontinue Dupixent until resolves. Do not inject into tender, damaged, bruised or scarred skin. Pregnancy. Nursing mothers.

Pharmacologic Class:

Interleukin-4 receptor alpha antagonist.

Interactions:

Avoid concomitant live vaccines.

Adverse Reactions:

Inj site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, oropharyngeal pain, eosinophilia, insomnia, toothache, gastritis, arthralgia; hypersensitivity.

Generic Availability:

NO

How Supplied:

Single-dose prefilled syringes—2 (with needle shield)

Pricing for DUPIXENT

2 syringes of 150mg/ml carton (Qty: 2)
Appx. price $2980
GoodRx

Miscellaneous respiratory disorders:

Indications for DUPIXENT:

As an add-on maintenance treatment in patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP).

Adult:

Give by SC inj into thigh, abdomen (except around navel), or upper arm; rotate inj sites. 300mg every other week.

Children:

<18yrs: not established.

Warnings/Precautions:

Discontinue if significant hypersensitivity reaction occurs; treat appropriately. Advise patients to report new onset or worsening eye symptoms. Avoid abrupt discontinuation of any corticosteroids upon Dupixent initiation. Atopic dermatitis or CRSwNP patients with co-morbid asthma. Treat pre-existing helminth infections prior to initiation; if infection develops and unresponsive to anthelmintics, discontinue Dupixent until resolves. Do not inject into tender, damaged, bruised or scarred skin. Pregnancy. Nursing mothers.

Pharmacologic Class:

Interleukin-4 receptor alpha antagonist.

Interactions:

Avoid concomitant live vaccines.

Adverse Reactions:

Inj site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye, oropharyngeal pain, eosinophilia, insomnia, toothache, gastritis, arthralgia; hypersensitivity.

Generic Availability:

NO

How Supplied:

Single-dose prefilled syringes—2 (with needle shield)

Pricing for DUPIXENT

2 syringes of 150mg/ml carton (Qty: 2)
Appx. price $2980
GoodRx